Skip to main content

GMAB Genmab A/S

Healthcare

37.07

Close 10/9

Open
36.55
High
37.15
Low
36.33
Prev close
36.05
Volume
2.3M
52W 23.62 40.17
Loading candles…

Is Genmab A/S a buy? Fundamentals and valuation first

As of 2026-10-09

Momentum: Strong, Risk / liquidity: Good.

Momentum Strong 60-day return is Top; 240-day return is Good.
60-day return (%) 27.92 92th percentile Top
240-day return (%) 24.02 76th percentile Good
Risk / liquidity Good 20-day dollar volume is Top; 60-day annualized volatility is Good.
20-day dollar volume 141,350,753 90th percentile Top
60-day annualized volatility (%) 35.82 40th percentile Good

Genmab A/S (GMAB) today

2 quant signals active · As of 2026-10-09

Win rate and excess are historical post-trigger stats vs the market. Click a signal for its full definition and samples; history does not predict future results.

Genmab A/S (GMAB) peers and tracking

Watchlist

This page refreshes daily after the close. Add Genmab A/S to your watchlist to track signal changes on your next visit.

Genmab A/S (GMAB) quant signal backtests

Signals active now

Each active condition is tested against this stock’s own history and benchmarked versus the S&P 500.

52-week adjusted-price high

Active

Adjusted close first reaches a 252-trading-day high; repeated hits within 20 days count once.

23 historical occurrences (since 2017-02-01)
Average forward return after 52-week adjusted-price high。20-day: Win 45.5%, Sample 22, Median -1.16%, Excess -1.01%, Beat mkt rate 36.4%；60-day: Win 63.6%, Sample 22, Median +1.74%, Excess -3.11%, Beat mkt rate 45.5%；120-day: Win 45.5%, Sample 22, Median -3.55%, Excess -8.36%, Beat mkt rate 36.4%

120 days after: historical avg +0.27%

20-day +0.43%
60-day +1.06%
120-day +0.27%
20-day
60-day
120-day
Win
45.5%
63.6%
45.5%
Sample
22
22
22
Median
-1.16%
+1.74%
-3.55%
Excess
-1.01%
-3.11%
-8.36%
Beat mkt rate
36.4%
45.5%
36.4%

Over 22 occurrences, 120-day forward avg gained 0.27%, lagged the market by 8.36 pts; win rate 45.5%.

Top-quintile 6-month momentum

Active · now 81.05%

The stock ranks in the top 20% of the liquid US common-stock universe by 126-day adjusted return.

28 historical occurrences (since 2016-07-05)
Average forward return after Top-quintile 6-month momentum。20-day: Win 48.1%, Sample 27, Median -0.04%, Excess -0.28%, Beat mkt rate 44.4%；60-day: Win 66.7%, Sample 27, Median +5.75%, Excess +0.5%, Beat mkt rate 55.6%；120-day: Win 59.3%, Sample 27, Median +6.41%, Excess +0.51%, Beat mkt rate 48.1%

120 days after: historical avg +6.65%

20-day +0.84%
60-day +3.23%
120-day +6.65%
20-day
60-day
120-day
Win
48.1%
66.7%
59.3%
Sample
27
27
27
Median
-0.04%
+5.75%
+6.41%
Excess
-0.28%
+0.5%
+0.51%
Beat mkt rate
44.4%
55.6%
48.1%

Over 27 occurrences, 120-day forward avg gained 6.65%, beat the market by 0.51 pts; win rate 59.3%.

More history: Market-wide momentum baseline

Market-wide momentum baseline

Across 98,394 liquid US common-stock samples, top-quintile 6-month momentum was followed by an average 60-trading-day return of +6.23%, a 57.8% positive-return rate, and +2.88 percentage points of average excess return versus the S&P 500.

Baseline: weekly samples since 2016 where a liquid US common stock ranked in the top quintile by 126-trading-day momentum. Forward return is 60 trading days; excess return is versus S&P 500 (^GSPC).

Continue researching Genmab A/S with the evidence above.

Continue in Studio ↗

Method and limits

  • Returns use us_price:adj_close, adjusted for splits and dividends where available.
  • Excess returns use world_index:^GSPC as the S&P 500 benchmark proxy.
  • Quarterly fundamentals are aligned to SEC filing dates before daily valuation studies.
  • The promoted universe starts from active NYSE/NASDAQ common stocks, then applies price and dollar-volume gates.
  • Snapshot-only tables such as analyst consensus, DCF, us_ratios, and us_key_metrics are intentionally excluded from historical evidence.
  • Overlapping event windows are descriptive distributions, not independent samples.
  • This is an American depositary receipt (ADR). The data does not say how many ordinary shares each ADR represents, so per-share and market-value metrics (P/E, price/book, free-cash-flow yield, EPS growth and earnings surprises) are not computed.
  • ADRs listed on NYSE or NASDAQ are covered as a separate group selected by dollar volume, in addition to the common-stock universe; the 6-month momentum signal ranks each ADR against the liquid US common stocks.
  • The company has reported its financial statements in more than one currency, so margins, growth and valuation figures that would combine them are not computed.

This page is for historical data analysis and education only. It is not investment advice. Backtests and historical return distributions do not predict future performance; evaluate risk independently before trading.